Summary
Cannot evaluate alignment because the prompt does not provide an AI-generated narrative/claims as a single auditable response against the provided FDA label product labeling. Only a list of claims is provided, but the evaluation cannot be mapped to the specific label indications/product scope beyond the hemophilia-tooth-extraction excerpts; therefore support/contradiction for most claims cannot be verified from the supplied label text.
Category Scores
Accurate Statements
Tranexamic acid is an antifibrinolytic agent.
Supported by label mechanism: 12.1 states tranexamic acid diminishes dissolution of hemostatic fibrin by plasmin, preserving/stabilizing fibrin.
Unsupported Statements
Tranexamic acid injection is primarily used to control and prevent excessive bleeding.
Not supported by supplied label excerpts, which only show an indication for hemophilia patients undergoing tooth extraction. The provided label text does not substantiate broad 'primarily used' claims.
Tranexamic acid achieves its effect by inhibiting the breakdown of blood clots (fibrinolysis).
Partially overlaps label mechanism but the supplied label does not explicitly use 'fibrinolysis' wording; cannot confirm this phrasing from the excerpt alone.
Tranexamic acid stabilizes blood clots, making them more resistant to degradation.
Label supports preserving/stabilizing fibrin’s matrix structure (12.1), but does not explicitly state 'blood clots' or 'more resistant to degradation' in the provided excerpt; cannot fully confirm the claim wording.
Tranexamic acid is used for heavy menstrual bleeding to reduce blood loss.
Not supported by supplied label indication excerpt (hemophilia tooth extraction only).
Tranexamic acid is used to treat postpartum hemorrhage (excessive bleeding after childbirth).
Not supported by supplied label indication excerpt.
Tranexamic acid injection can be administered to reduce bleeding during and after surgical procedures.
Not supported by supplied label indication excerpt.
Tranexamic acid injection is used for surgical bleeding in procedures including dental surgery, ear/nose/throat surgeries, and orthopedic operations.
Not supported by supplied label indication excerpt (only tooth extraction in hemophilia).
In severe trauma, tranexamic acid can help mitigate life-threatening blood loss.
Not supported by supplied label indication excerpt.
Tranexamic acid may be used to help control gastrointestinal bleeding.
Not supported by supplied label indication excerpt.
Tranexamic acid is used to manage bleeding associated with certain medical conditions or treatments, including after prostate surgery and in patients with hemorrhagic cystitis.
Not supported by supplied label indication excerpt.
Tranexamic acid works by reversibly binding to plasminogen.
The provided 12.1 excerpt mentions plasmin and dissolution of fibrin but does not explicitly state reversible binding to plasminogen.
Plasmin is an enzyme that breaks down fibrin.
The provided excerpt describes plasmin’s role in dissolution of hemostatic fibrin, but the claim is definitional ('plasmin is an enzyme') and not explicitly stated in provided label wording.
By binding to plasminogen, tranexamic acid prevents plasmin from forming.
Not supported by the provided 12.1 excerpt, which does not state prevention of plasmin formation via plasminogen binding.
By preventing plasmin formation, tranexamic acid reduces the dissolution of blood clots.
Not supported by the provided 12.1 excerpt; also uses 'blood clots' and 'preventing plasmin formation' not explicitly supported.
Common side effects of tranexamic acid injection may include gastrointestinal upset such as nausea, vomiting, or diarrhea.
Not supported by provided adverse reaction sections; only clinically significant adverse reactions listed are thromboembolic risk, seizures, hypersensitivity, visual disturbances, and dizziness, with post-marketing items (e.g., hypotension when IV injection is too rapid; cromatopsia/visual impairment; anaphylaxis). No GI upset is supported in provided excerpts.
More serious, though rare, side effects of tranexamic acid injection can include allergic reactions.
Hypersensitivity reactions/anaphylaxis are mentioned, but the claim does not map cleanly to provided excerpt phrasing ('allergic reactions' and 'rare' are not explicitly supported).
More serious, though rare, side effects of tranexamic acid injection can include dizziness.
Dizziness is described (5.5) but 'more serious, though rare' is not supported by provided label excerpts.
More serious, though rare, side effects of tranexamic acid injection can include vision disturbances.
Visual disturbances are described (5.4), but 'more serious, though rare' is not supported by provided label excerpts.
A significant concern with tranexamic acid is the potential risk of blood clots (thrombosis).
Thromboembolic risk is described, but 'blood clots (thrombosis)' is not exact label phrasing; cannot confirm severity/wording ('significant concern').
The risk of thrombosis is particularly relevant in individuals with pre-existing risk factors or those taking hormonal contraceptives.
Label explicitly mentions increased risk with hormonal contraceptives (5.1; 8.3), but does not provide support in the supplied excerpts for 'pre-existing risk factors' wording.
Use of tranexamic acid requires careful medical evaluation.
Label does not explicitly state this general instruction in provided excerpts (e.g., no 'careful medical evaluation' wording).
Information on specific patent expiry dates for tranexamic acid formulations is typically found through specialized patent databases.
Not supported by the provided FDA label excerpts (non-drug-content informational claim).
Tranexamic acid is an older, well-established medication.
Not supported by provided FDA label excerpts.
Many original patents for tranexamic acid have likely expired, leading to the availability of generic versions.
Not supported by provided FDA label excerpts.
Contradictions
Important Omissions
The claims do not reflect the specific labeled indication scope shown in the provided label excerpt (hemophilia patients for short-term use 2 to 8 days to reduce/prevent hemorrhage and reduce replacement therapy during and following tooth extraction).
Importance:
Moderate
The claims do not include key labeled administration/dosing details for the specified indication (10 mg/kg IV single dose immediately before tooth extraction; post-extraction dosing 2 to 8 days 10 mg/kg three to four times daily IV; infusion rate limit to avoid hypotension; renal dose reduction guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Although several claims are not supported by the supplied label excerpts (especially broad off-scope bleeding uses and mechanistic/pharmacology phrasing), the evaluation is limited to on-label excerpt alignment. The only clearly supported mechanistic concept is antifibrinolytic activity; many other claims cannot be confirmed from provided label text, increasing overall label-alignment risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Most claims extend beyond the provided labeled indication and are not supported by the supplied FDA label excerpts; mechanistic details and side effect descriptions use wording not explicitly supported in the provided text.
Suggested Improvement
Restrict claims to the supplied label excerpt scope (hemophilia tooth extraction indication; labeled dosing/infusion timing and renal adjustment; labeled contraindications and listed clinically significant adverse reactions/warnings). Use label-supported wording for mechanism (diminishes dissolution of hemostatic fibrin by plasmin; preserving/stabilizing fibrin matrix) and for adverse reactions (thromboembolic risk, seizures, hypersensitivity/anaphylaxis, visual disturbances, dizziness). Avoid unsupported generalizations about other bleeding indications, patent status, or general history without label support.